Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence.

Peter P TothSergio FazioNathan D WongMichael HullGregory A Nichols

Published in: Diabetes, obesity & metabolism (2019)

Real-world analyses suggest that elevated TGs are prevalent and commonly associated with increased CV risk. CV outcomes trials in patients with established hypertriglyceridaemia will clarify whether strategies to reduce TG levels can ameliorate residual CV risk in patients taking statins.

Keyphrases

cardiovascular events
end stage renal disease
cardiovascular disease
coronary artery disease
chronic kidney disease
ejection fraction
newly diagnosed
metabolic syndrome
patient reported outcomes
skeletal muscle
patient reported
insulin resistance